Reported 9 months ago
The article discusses how pandemic vaccine giants Moderna and Pfizer have seen their stocks plummet by over 30% in recent years due to weakening demand for vaccines. Despite this, both companies are undergoing transitions and have promising long-term prospects. Moderna is diversifying its product portfolio with new vaccines and therapies, while Pfizer is preparing for potential revenue growth through new products and mergers. Investors are advised that the current stock prices present a good buying opportunity with potential for growth in the future.
Source: YAHOO